Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 305-748-4 | CAS number: 95009-22-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Respiratory sensitisation
Administrative data
- Endpoint:
- respiratory sensitisation
- Remarks:
- other: Ex vivo study on guinea pig trachea, relating to respiratory sensitisation and irritation.
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable, well-documented publication which meets basic scientific principles.
Cross-reference
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- publication
- Title:
- Pharmacologic effects of cocoa and rye flour extracts on isolated guinea pig trachea
- Author:
- Schachter E.N., Zuskin E., Rienzi N. and Goswami S.
- Year:
- 1 999
- Bibliographic source:
- Journal of Toxicology and Environmental Health Part A, 56, 137-148
Materials and methods
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Ex vivo study on isolated guinea pig trachea to evaluate contraction in response to treatment with a cocoa extract at up to 50 μl/ml.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Cocoa ext.
- IUPAC Name:
- Cocoa ext.
- Reference substance name:
- Cocoa, ext.
- EC Number:
- 283-480-6
- EC Name:
- Cocoa, ext.
- Cas Number:
- 84649-99-0
- IUPAC Name:
- 283-480-6
- Details on test material:
- - Name of test material (as cited in study report): cocoa extract
- Substance type: no data
- Physical state: in aqueous solution
- Analytical purity: no data
- Impurities (identity and concentrations): no data
- Composition of test material, percentage of components: the 10% extract contained 45 μg/ml protein
- Isomers composition: no data
- Purity test date: no data
- Lot/batch No.: no data
- Expiration date of the lot/batch: no data
- Stability under test conditions: no data
- Storage condition of test material: -20 °C
- Other: dust extracts were prepared from cocoa collected from machines in a Croatian confectionery plant. In preparing the extract, the allergen raw material was defatted with diethyl ether, and then stirred in phosphate-buffered saline for 72 hours at 4 °C. The extract was then centrifuged and purified.
Constituent 1
Constituent 2
Results and discussion
Applicant's summary and conclusion
- Conclusions:
- A 10% cocoa extract significantly induced dose-related contraction in isolated guinea pig tracheal segments. Blocking agents, particularly atropine, significantly inhibited this contraction. The results suggest cocoa extract can induce airway contraction via non-immunological mechanisms.
- Executive summary:
An ex vivo study has been conducted on segments from the tracheas of non-sensitised guinea pigs in order to elucidate the mechanisms by which cocoa extract can induce airway constriction.
Tracheas from 18 males were removed and each cut into four rings. These were suspended in a 20 ml organ chamber. One ring from each guinea pig was exposed to increasing concentrations of 10, 30, 100, 300 and 1000μl [0.5, 1.5, 5, 15 and 50μl/ml] of a 10% cocoa extract. The other three rings were pre-treated for 30 minutes with one of nine blocking agents, and were then exposed to the cocoa extract at the same five concentrations.
Cocoa extract caused significant, dose-related contraction, with an Emax(observed maximal muscle tension as a percentage of the maximal contraction induced by 0.1 mmol/L of carbachol) of 125.3±7.9%. The average EC50 (the concentration eliciting half of the cocoa extract’s maximal response) was 30.09±6.7μl [1.5± 0.3 μl/ml]. Contraction was significantly inhibited by each blocking agent.
The results were said to suggest “a complex interaction between” this airway irritant and “guinea pig tracheal tissue”, and that “clinical effects of cocoa … in workers are probably related to non-immunologic (non-IgE) mechanisms similar to those seen with other organic dusts extracts”. In particular, cholinergic mediators were seen to play a key role in airway constriction, as atropine (which is anticholinergic) almost completely blocked constriction.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
